BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21195307)

  • 1. What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
    Giralt S; Stadtmauer E; McCarthy P
    Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S30-2. PubMed ID: 21195307
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
    SanMiguel J; Facon T; Cavo M
    Clin Adv Hematol Oncol; 2008 Apr; 6(4):s4-s10. PubMed ID: 18567204
    [No Abstract]   [Full Text] [Related]  

  • 3. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.
    Hahn T; Wingard JR; Anderson KC; Bensinger WI; Berenson JR; Brozeit G; Carver JR; Kyle RA; McCarthy PL
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):4-37. PubMed ID: 12533739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
    Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma].
    García Laraña J; Díaz Mediavilla J; Martínez R; Lahuerta JJ; Alegre A; Odriozola J; Sureda A; San Miguel J; De la Rubia J; Escudero A; Conde E; Bladé J; Cabrera R; Gastearena J; Besalduch J; Vidal MJ; Hernández F; Rifon J; Leon A; Mataix R; Parody R; Moraleda JM; Solano C; de Pablos JM; Sánchez JJ
    Sangre (Barc); 1997 Apr; 42 Suppl 1():38-41. PubMed ID: 9381300
    [No Abstract]   [Full Text] [Related]  

  • 8. [Physiopathology, diagnosis and therapy in multiple myeloma (discussion)].
    Nihon Naika Gakkai Zasshi; 1995 Jul; 84(7):1132-49. PubMed ID: 7561372
    [No Abstract]   [Full Text] [Related]  

  • 9. [Progress in the study of autologous hematopoietic stem cell transplantation therapy of multiple myeloma].
    Zhang M; Son K
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jun; 19(6):331-3. PubMed ID: 11243115
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
    Hussein M
    Leukemia; 2004 Apr; 18(4):893. PubMed ID: 14973496
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study.
    Feyler S; Rawstron A; Jackson G; Snowden JA; Cocks K; Johnson RJ
    Br J Haematol; 2007 Nov; 139(3):429-33. PubMed ID: 17910633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of multiple myeloma: melphalan--40 years old and still going strong.
    Bergsagel PL
    Biol Blood Marrow Transplant; 2003 Jan; 9(1):2-3. PubMed ID: 12533738
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of autologous stem cell transplantation in the management of multiple myeloma.
    Fermand JP; Brechignac S
    Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
    Vesole DH; Simic A; Lazarus HM
    Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multiple myeloma--advances in disease biology and implications for therapy].
    Chou T
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1206-12. PubMed ID: 11579631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of autologous stem-cell transplantation in multiple myeloma.
    Attal M; Harousseau JL
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel approaches in myeloma therapy.
    Munshi NC; Barlogie B; Desikan KR; Wilson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 13):28-34. PubMed ID: 10528892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients.
    Martino M; Console G; Callea V; Stelitano C; Massara E; Irrera G; Messina G; Morabito F; Iacopino P
    Eur J Haematol; 2007 Jan; 78(1):35-40. PubMed ID: 17042773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous hematopoietic stem-cell transplantation for multiple myeloma.
    Harousseau JL; Moreau P
    N Engl J Med; 2009 Jun; 360(25):2645-54. PubMed ID: 19535803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.